Dong Xin, Xie Yafei, Xu Jianguo, Qin Yu, Zheng Qingyong, Hu Rui, Zhang Xin, Wang Wenxin, Tian Jinhui, Yi Kang
Department of Ultrasound, Gansu Provincial Hospital, Lanzhou, China.
Gansu International Scientific and Technological Cooperation Base of Diagnosis and Treatment of Congenital Heart Disease, Lanzhou, China.
Heliyon. 2023 Feb 7;9(2):e13509. doi: 10.1016/j.heliyon.2023.e13509. eCollection 2023 Feb.
Heart failure is a rapidly growing public health problem and has become a major cause of hospitalization in middle-aged and older adults. Biomarkers are clinically important in managing heart failure and have attracted more attention from researchers in recent years. This study aimed to evaluate the global research of heart failure biomarkers by bibliometrics and to identify the hot spots and perspectives for further advancement.
Selection of relevant documents was from the Web of Science Core Collection. Microsoft Excel, VOSviewer, SciMA, and CiteSpace software were used for bibliometric analysis.
As of October 29, 2021, 5,978 documents for heart failure biomarkers have been identified from 1989 to 2021. and respectively ranked first in terms of the number of publications and the number of co-citations. A total of 5,698 institutions from 90 countries participated in these publications, with the USA leading with 2,045 documents. The most productive institution was Harvard University. Januzzi, J.L. and Maisel, A.S. were the most productive and most cited authors respectively. Natriuretic peptide, copeptin, valsartan, ferric carboxymaltose, empagliflozin, preserved ejection fraction, myocardial fibrosis, and heart transplantation were hot themes.
Extensive national and inter-institutional collaboration should be enhanced to bridge the gap between developed and less developed countries in heart failure biomarkers research. The research in this field seems to have reached a relatively mature stage, with a decrease in research fervor in recent years. The study of the natriuretic peptide family still has high centrality, with advances in the study of expression products and inflammatory markers. Cardiac fibrosis, cardiac remodeling, and therapies regarding heart failure have become hot spots.
心力衰竭是一个迅速发展的公共卫生问题，已成为中老年人群住院的主要原因。生物标志物在心力衰竭管理中具有重要临床意义，近年来受到了研究人员更多的关注。本研究旨在通过文献计量学评估心力衰竭生物标志物的全球研究情况，并确定进一步发展的热点和前景。
从科学引文索引核心合集（Web of Science Core Collection）中选择相关文献。使用微软Excel、VOSviewer、SciMA和CiteSpace软件进行文献计量分析。
截至2021年10月29日，1989年至2021年期间共识别出5978篇关于心力衰竭生物标志物的文献。 在发表数量和共被引次数方面分别排名第一。来自90个国家的5698个机构参与了这些文献的发表，美国以2045篇文献领先。产出最多的机构是哈佛大学。Januzzi, J.L.和Maisel, A.S.分别是产出最多和被引次数最多的作者。利钠肽、 copeptin、缬沙坦、羧麦芽糖铁、恩格列净、射血分数保留、心肌纤维化和心脏移植是热门主题。
应加强广泛的国家和机构间合作，以弥合发达国家和欠发达国家在心力衰竭生物标志物研究方面的差距。该领域的研究似乎已达到相对成熟的阶段，近年来研究热度有所下降。利钠肽家族的研究仍具有较高的中心性，其表达产物和炎症标志物的研究取得了进展。心脏纤维化、心脏重塑和心力衰竭治疗已成为热点。
